---
title: "PSPA 31 - Patient Medication Risk Education"
date: "2020-02-27T20:56:42.313Z"
url: "general-functionality/quality-of-care/measures/improvement-activities-measures/2019-improvement-activities/pspa-31-patient-medication-risk-education.html"
version: 12
id: "1QPm-3oew_1L-aVTYue5l3m5S0-OZ2j-X4CtkhCejJT0"
source: "https://drive.google.com/open?id=1QPm-3oew_1L-aVTYue5l3m5S0-OZ2j-X4CtkhCejJT0"
menu:
    main:
        name: "PSPA 31 - Patient Medication Risk Education"
        identifier: "1QPm-3oew_1L-aVTYue5l3m5S0-OZ2j-X4CtkhCejJT0"
        parent: "1vu04nEcej6Kmg0Fpjl-pYKDOeJgJVXVbWhmyZXYgVcU"
        weight: 3740
---








**Activity Weighting**: High

**Subcategory Name**: Patient Safety and Practice Assessment

**Description**: In order to receive credit for this activity, MIPS eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. 







## 

Supporting Documentation

Education must be completed for at least 75% of qualifying patients and occur:

* at the time of initial co-prescribing and again following greater than 6 months of co- prescribing of benzodiazepines and opioids, or 
* at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.







## 

Resources

[2018 Improvement Activities Requirements](https://qpp.cms.gov/mips/improvement-activities?py=2018)

[2019 Improvement Activities Requirements](https://qpp.cms.gov/mips/improvement-activities?py=2019)

[2018 MIPS Improvement Activities Fact Sheet](https://qpp.cms.gov/resource/2018%20MIPS%20Improvement%20Activities%20Fact%20Sheet)

[Scores for Improvement Activities for MIPS APMs in the 2018 Performance Period Fact Sheet](https://qpp.cms.gov/resource/2018%20MIPS%20APMs%20improvement%20Activities%20scores%20fact%20sheet)

